{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-045585","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.100221+00:00","generated_at":"2026-05-25T14:01:26.232833+00:00","sec_items":["8.01","7.01","9.01"],"event_type":"other","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"REGENXBIO closes strategic partnership with Nippon Shinyaku for MPS gene therapies","bullets":["Partnership closed for development/commercialization of RGX-121 (MPS II) and RGX-111 (MPS I) in US and Asia.","RGX-121 on track as first gene therapy for MPS II; potential FDA approval as early as late 2025.","CEO Curran Simpson highlights transformative potential for MPS patient populations.","No financial terms disclosed in this filing; partnership was previously announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-045585","json":"https://secwatch.observer/filing/0001193125-25-045585.json","markdown":"https://secwatch.observer/filing/0001193125-25-045585.md","text":"https://secwatch.observer/filing/0001193125-25-045585.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000119312525045585/0001193125-25-045585-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000119312525045585/d909911d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T14:01:26.232833+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}